P3-064: Gefitinib (Gefitinat) in advanced non small cell lung cancer-a follow up observation in Indian patients
نویسندگان
چکیده
منابع مشابه
Gefitinib in Non Small Cell Lung Cancer
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials with gefit...
متن کاملGefitinib for advanced or metastatic non-small cell lung cancer.
Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment and docetaxel chemotherapy. Its efficacy when compared to standard treatment and best supportive care is unproven. Common drug-related adverse effects include gastrointestinal and skin disorders. Rare but serious d...
متن کاملGefitinib monotherapy in advanced non-small cell lung cancer: Experience from a large, Western community, implementation study. Running title: Gefitinib for advanced non-small cell lung cancer (NSCLC)
Authors: R. van Puijenbroek, L. Bosquée, A-P. Meert, D. Schallier, J-C. Goeminne, G. Tits, P. Collard, K. Nackaerts, J-L Canon, F. Duplaquet, D. Galdermans, P. Germonpré, M-A. Azerad, G. Vandenhoven, J. De Greve, J. Vansteenkiste. Affiliations: Univ. Hospital, Catholic University, Leuven Citadelle Hospital, Liège Jules Bordet Institute, Brussels Univ. Hopsital VUB, Brussels St-Elisabeth Hospita...
متن کاملObservation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer
To observe drug-induced hepatotoxicity by long-term gefitinib administration in the treatment of non-small-cell lung cancer. The data of 101 patients with locally advanced or metastatic non-small-cell lung cancer, for which gefitinib had been used orally for 3 months or longer, were retrospectively analyzed. The median duration of gefitinib administration was 14 months (3-60 months). Forty pati...
متن کاملGefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, progressive NSCLC, previously treated with chemotherapy, received oral gefitinib 250 mg daily. The fir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2007
ISSN: 1556-0864
DOI: 10.1097/01.jto.0000284040.48587.7e